The academic and drug development expert Bams Abila has joined Immodulon Therapeutics Ltd as chief medical officer to help the company progress its lead drug candidate for cancer. Professor Abila most recently served as CMO for the contract research organisation Cmed Technology Ltd and was principle consultant at Clintreq Consultancy Ltd. In 2015, he was appointed as a visiting professor of biologics and advanced therapy drug development at King’s College London. Prof Abila earned a doctorate in medicine from the University of Ibadan in Nigeria as well as a doctorate in medicine and clinical pharmacology from the University of Wales in the UK.
Immodulon announced the appointment on 8 August 2019.
Copyright 2019 Evernow Publishing Ltd.